Moksifloksacin Pharmas (Moxifloxacin)

Moxifloxacin is a fluoroquinolone antibacterial used to manage a range of serious bacterial infections.

• Community‑acquired bacterial pneumonia: eradicates susceptible pathogens and improves clinical recovery.
• Acute bacterial sinusitis: reduces bacterial load and relieves sinus inflammation.
• Acute bacterial exacerbation of chronic bronchitis: shortens symptom duration and prevents complications.
• Skin and skin‑structure infections: eliminates causative bacteria and promotes wound healing.
• Intra‑abdominal infections: provides broad‑spectrum coverage for mixed aerobic and anaerobic organisms.

• Moxifloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. By binding to these enzymes, it prevents the unwinding and resealing of DNA strands, leading to bacterial cell death and a bactericidal effect against susceptible Gram‑positive and Gram‑negative organisms.

Moxifloxacin may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Diarrhea: loose stools, sometimes watery.
• Headache: transient cranial discomfort.
• Dizziness: sensation of light‑headedness.
• Rash: mild skin erythema or itching.
• Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects

• Tendon rupture: especially Achilles tendon, may occur without warning.
• QT interval prolongation: can precipitate ventricular arrhythmias.
• Severe allergic reactions: anaphylaxis, angioedema, or Stevens‑Johnson syndrome.
• Clostridioides difficile infection: colitis associated with antibiotic use.
• Hepatic failure: rare but potentially life‑threatening liver injury.
• Anaphylactic shock: immediate hypersensitivity requiring emergency care.

Before initiating therapy, consider patient‑specific factors and monitor for potential complications.

• Renal impairment: adjust dosing according to renal function and monitor creatinine.
• Hepatic impairment: assess liver enzymes and use with caution in severe disease.
• QT prolongation risk: avoid in patients with known cardiac arrhythmias or electrolyte disturbances.
• Concurrent fluoroquinolone therapy: avoid to prevent additive toxicity.
• Pregnancy and lactation: use only if the expected benefit justifies the potential risk.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Moxifloxacin can interact with several drug classes, altering efficacy or safety.

Major Interactions (Avoid)

• Other fluoroquinolones: increased risk of tendon toxicity and cumulative QT prolongation.
• QT‑prolonging agents (e.g., macrolides, antiarrhythmics): heightened risk of serious cardiac arrhythmias.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may diminish antibacterial activity.
• Warfarin: potentiates anticoagulant effect, requiring INR monitoring.

Moderate Interactions (Monitor Closely)

• Corticosteroids: elevated risk of tendon rupture.
• Theophylline: may raise plasma theophylline concentrations.
• Cyclosporine: potential increase in moxifloxacin plasma levels.
• Antacids containing aluminum or magnesium: can reduce absorption of oral formulations (less relevant for IV).